4DMT Overview

  • Founded
  • 2015

Founded
  • Status
  • Public

  • Employees
  • 137

Employees
  • Stock Symbol
  • FDMT

Stock Symbol
  • Share Price
  • $8.74

  • (As of Thursday Closing)

4DMT General Information

Description

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 5858 Horton Street
  • Suite 455
  • Emeryville, CA 94608
  • United States
+1 (510) 000-0000

4DMT Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

4DMT Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.74 $8.95 $5.32 - $36.14 $290M 32.4M 249K -$3.36

4DMT Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 6,118 543,451 1,009,410
Revenue 2,840 18,038 13,612 6,986
EBITDA (99,166) (68,434) (55,402) (49,806)
Net Income (101,746) (71,317) (56,693) (49,306)
Total Assets 302,936 353,487 288,331 58,234
Total Debt 16,998 16,448 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

4DMT Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 4DMT‘s full profile, request access.

Request a free trial

4DMT Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore 4DMT‘s full profile, request access.

Request a free trial

4DMT Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates usi
Biotechnology
Emeryville, CA
137 As of 2022
00000
00000000 00000

000000

ore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
0000 00.000

000000

ation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderi
0000000000000
London, Canada
00 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

4DMT Competitors (58)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
0000000 Corporation London, Canada 00 000.00 00000000 000.00
0000000 0000000000 Corporation Waconia, MN 0 000.00 00000000 000.00
0000000 0000000000 Formerly VC-backed Redwood City, CA 000 00000 00000000000 00000
0000000000 0000000 Formerly VC-backed Novato, CA 0000 00000 000000000 00000
You’re viewing 5 of 58 competitors. Get the full list »

4DMT Patents

4DMT Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220062438-A1 Codon optimized rep1 genes and uses thereof Granted 02-Sep-2020 000000000
US-11357870-B2 Codon optimized rep1 genes and uses thereof Active 02-Sep-2020 000000000 0
US-20220064673-A1 Codon optimized rpgrorf15 genes and uses thereof Granted 02-Sep-2020 000000000
US-11345930-B2 Codon optimized rpgrorf15 genes and uses thereof Active 02-Sep-2020 000000000 0
US-11198858-B2 Codon optimized gla genes and uses thereof Active 27-Apr-2020 C12N9/2465
To view 4DMT’s complete patent history, request access »

4DMT Executive Team (12)

Name Title Board Seat Contact Info
David Kirn MD Chief Executive Officer & Founder
August Moretti JD Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Fred Kamal Ph.D Chief Technology Officer, Technology & Chief Operating Officer, Operations
Nadine Greiner Ph.D Chief Human Resources Officer
Theresa Janke Founder & Executive
You’re viewing 5 of 12 executive team members. Get the full list »

4DMT Board Members (14)

Name Representing Role Since
Charles Theuer MD Self Board Member 000 0000
David Schaffer Ph.D Self Co-Founder, Chief Scientific Advisor & Board Member 000 0000
Jacob Chacko MD Self Board Member 000 0000
John Milligan Ph.D Self Executive Chairman 000 0000
Nancy Miller-Rich Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

4DMT Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

4DMT Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 4DMT‘s full profile, request access.

Request a free trial